In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IntraLuminal Therapeutics Inc.

Division of Royal DSM NV
www.intraluminal.com

Latest From IntraLuminal Therapeutics Inc.

Total Occlusions: Device Obstacle or Opportunity?

The market is promising for using catheters, instead of surgery, to open vascular blockages. But the right technology remains elusive.
Medical Device Clinical Trials

LuMend's Breakthrough Break Out

For many device companies and their investors, drug-eluting stents have come to represent a kind of technological end-game, a device so successful at solving an important unmet need that all future opportunities lie elsewhere. But, in fact, there are still many important unsolved problems in interventional cardiology, not the least of which is chronic total occlusions, lesions so thick and dense that blood can't flow through the artery. That's the problem LuMend has set out to solve and it has the first US-approved device on the market. And while some question the company's timing, LuMend officials argue they couldn't be better timed, since their device and drug-eluting stents go hand in hand.
Medical Device Platform Technologies

LuMend Inc.

Developing a device to percutaneously cross total occlusions.
Medical Device Platform Technologies

IntraLuminal Therapeutics Inc.

IntraLuminal Therapeutics is developing a new guidance system designed to help interventional cardiologists safely cross total occlusions.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Royal DSM NV
  • Senior Management
  • Allan D Hedrick, Pres. & CEO
    Karl James, VP, Fin.
    Glenn Latham, VP, Sales & Mktg.
    John M Neet, EVP & CTO
    Jerry Johansen, VP, Dev.
  • Contact Info
  • IntraLuminal Therapeutics Inc.
    Phone: (760) 918-1820
    6354 Corte Del Abeto
    Ste. A
    Carlsbad, CA 92009
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register